###### Strengths and limitations of this study

-   Blinded randomised design with placebo control.

-   Standardised protocols used for excision and follow-up.

-   Low baseline infection rate in women meant underpowered to draw conclusions for this subgroup.

Introduction {#s1}
============

Though limited published evidence is available to support or refute the use of oral antibiotic prophylaxis for prevention of surgical site infection (SSI) in dermatological surgery, several authorities suggest considering it for selected high-risk cases.[@R1]

As the ears and noses are especially vulnerable to ultraviolet (UV) radiation, generally being uncovered and protruding from the body, skin cancers are more commonly found at these sites than most other body sites.[@R5] Furthermore, the cancers that develop on the nose and ear are more likely to be of an aggressive subtype[@R6] requiring wider excision margins and subsequent flap or graft surgical repair for optimal cosmetic and functional outcome. The body site and the need for complex closure put patients with auricular or nasal skin cancers at significantly higher risk of SSI than is normally observed for clean dermatological surgery.[@R1]

Despite the paucity of evidence for dermatological antibiotic prophylaxis, first-generation cephalosporins or penicillinase-resistant penicillins are generally recommended as *Staphylococcus aureus* and *Streptococci* are the most prevalent bacteria causing SSI.[@R1] Oral cephalexin or dicloxacillin given as a 2 g oral dose 30--60 min before the procedure has been recommended by several authorities.[@R1]

The aim of this study was to determine whether the use of a single 2 g dose of cephalexin given 40--60 min prior to surgery would significantly reduce infection rates following complex auricular and nasal dermatological surgery.

Method {#s2}
======

Consecutive eligible patients booked for flap or graft closure following skin cancer excision on the ear and nose were recruited by six doctors (including the principal researcher HR) working at a primary care skin cancer clinic in Townsville, North Queensland, Australia, between December 2013 and March 2016. Study participation was allowed once only for each individual patient. All participants[@R2] gave signed informed consent.

Specific exclusion criteria ([figure 1](#F1){ref-type="fig"}) were aged under 18, intellectual or mental impairment affecting ability to give informed consent, allergy to the protocol suture or dressing materials, allergy to cephalosporins or penicillin, use of any antibiotic (other than the intervention) within 48 hours of the surgery and suspected SSI at the time of surgical closure. If pathology confirmed residual tumour and the need for a wider excision the participant was subsequently excluded from the study.

![Inclusion and exclusion criteria.](bmjopen-2017-020213f01){#F1}

All participants presented 30 min prior to their surgery for administration of capsules containing either 2 g cephalexin or a placebo. The initial skin incision was made 40--60 min after ingestion of capsules. Cephalexin was used because it has an antistaphylococcal activity and therefore covers organisms most likely to cause wound infection, but can be used in most patients with penicillin allergy and is cheaper than flucloxacillin.[@R2] Pharmacokinetic data show average peak dose serum levels of approximately 19 µg/mL at 1 hour following a 500 mg dose.[@R8] A 2 g dose has been used effectively in previous studies.[@R8] Baseline demographic data, relevant medical and drug history, histology, defect size, time from intervention to surgery and closure technique were documented at the time of surgery.

Modified Mohs micrographic surgery {#s2a}
----------------------------------

We used an adaptation of classical Mohs micrographic surgery (MMS) for patients with biopsy-proven aggressive tumours that had indistinct margins or were 10 mm or larger. The wound was left open under a dressing for 2 days awaiting complete histological deep and peripheral margin analysis using traditional H&E staining of wax-embedded samples in a pathology laboratory. Further excision and detailed histological analysis was undertaken if required with the wound only being closed once histology confirmed complete excision. It is known that SSI following secondary intention healing is very low,[@R9] hence antibiotic or placebo was only given prior to the actual flap or graft wound closure.

Intraoperative and postoperative protocol {#s2b}
-----------------------------------------

Nylon sutures (Dynek, Hendon, South Australia) were used superficially for all defect closures. Where deep dermal absorbable sutures were deemed necessary, Monosyn (B Braun Australia) was used. Melolin (Smith and Nephew Medical, Hull, UK) and Fixomull (BSN Medical Luxembourg) were applied to wounds immediately after surgery. Participants were asked not to use topical creams, ointments or antiseptics on their wounds postoperatively and were given standardised written and verbal instructions on postoperative wound care. Early wound review was encouraged in the event of any participant concern. Sutures were removed 5--7 days postoperatively. Any wound that had not fully healed was redressed until the defect had fully epithelialised.

Clinical outcome {#s2c}
----------------

Though there is no validated gold-standard definition for SSI, the 1988 Centers of Disease Control and Prevention of National Nosocomial Infections Surveillance System definition[@R11] has been widely adopted in Australia, USA and Europe. We used an adapted version of this definition ([figure 2](#F2){ref-type="fig"}). The superficial surgical site skin infection had to occur within 30 days of surgery and at least one of the following wound characteristics had to be present:purulent dischargelocalised swelling, pain or heaterythema \>1 cm from wound edgespatient report of increasing tenderness.
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Using this classification, if SSI was suspected by the treating doctor a swab was taken for microbiology culture and sensitivity and a 5-day course of cephalexin (500 mg four times per day) prescribed pending swab results.

The study nurse phoned participants 1 month postoperatively to cross-check if Dermatological Surgical Site Infection (DSSI) or any other complication had occurred helping to ensure that this had not been inadvertently missed.

Randomisation and blinding {#s2d}
--------------------------

The randomisation sequence, generated off-site electronically by author and statistician PGB, was sent to a compounding pharmacy in Townsville. Here batches of generic gel capsules were filled with either cephalexin (intervention) or microcrystalline cellulose and calcium carbonate (placebo) and sent to the recruiting practice in small screw top containers numbered according to the randomisation sequence. Each numbered container held four identical-looking gel capsules filled with either 500 mg cephalexin or placebo. Staff and participants at the recruiting clinic remained blinded to group allocation until the study had been completed.

Sample size {#s2e}
-----------

The infection rate for complex auricular and nasal dermatological surgery in a small observational survey at out clinic prior to commencing this study was around 20%. Our hypothesis was that antibiotic prophylaxis would reduce SSI fivefold from 20% to 4%. To show this with statistical confidence (power in excess of 80%; significance level 0.05), 59 patients were required in each study group. Allowing for a 20% drop-out it was planned to recruit 142 participants (71 intervention and 71 placebo).

Statistical analysis and presentation {#s2f}
-------------------------------------

Numerical data were described using mean and SD when symmetrically distributed and median and IQR when skewed. Categorical data were presented using absolute and relative frequencies.

Eligible non-participants were compared with participants using unpaired t-test, χ^2^ and Fisher's exact test. Intervention and control group differences at baseline as well as treatment modality differences were assessed using unpaired t-test, Mann-Whitney U test, χ^2^ and Fisher's exact test.

The main analysis comparing intervention and control groups with regards to SSI was modified by intention-to-treat (ITT) analysis based on available cases at follow-up and adhered to Consolidated Standards of Reporting Trials (CONSORT) guidelines.[@R12] Furthermore, ITT analysis was conducted assuming that: (1) none of the lost to follow-up cases had developed SSI and (2) all lost to follow-up cases had developed SSI.

Incidence of wound infection was compared between intervention and control groups using Fisher's exact test. The differences in infection rates and number needed to treat for benefit (NNTB) were calculated with 95% CIs.[@R13]

χ^2^ test and Fisher's exact test were used to compare postoperative complications, adverse effects and treatment of established postoperative infections between intervention and control groups.

Analysis was conducted using SPSS V.21 (IBM SPSS). A significance level of 0.05 was assumed. All statistical tests were conducted two sided.

Results {#s3}
=======

Of 199 consecutive patients requiring flap or graft closures on the nose or ear, 20 were ineligible due to penicillin or cephalosporin allergy (11), intellectual impairment (4) or taking antibiotics for other reasons within 48 hours of their skin surgery (5). See [figure 3](#F3){ref-type="fig"} for CONSORT flow diagram.
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Twenty-five eligible patients opted not to participate most commonly as they were unwilling to take unnecessary medication (14). Other reasons for non-participation (11) included fear of diarrhoea or allergy, difficulty swallowing tablets and not having time to come in 30 min ahead of the scheduled appointment.

Inadvertently, 12 more participants were recruited than planned resulting in a total of 154 participants. The participants were slightly older (mean age 66.3 years) and more likely to be female (71, 46.1%) than the 25 eligible non-participants (mean age 63.2 years; 8 female). Otherwise no difference was found between participants and non-participants ([table 1](#T1){ref-type="table"}).

###### 

Comparison of participants with non-participants who fulfilled inclusion criteria

  Characteristic                         Participants (n=154)   Eligible patients who did not participate (n=25)
  -------------------------------------- ---------------------- --------------------------------------------------
  Mean age (SD) (years)                  66.3 (11.1)            63.2 (12.2)
  Female                                 n=71 (46.1%)           n=8 (32.0%)
  Histology of lesion                                           
   BCC                                   n=117 (76.0%)          n=20 (80.0%)
   SCC                                   n=16 (10.4%)           n=3 (12.0%)
   IEC                                   n=20 (13.0%)           n=2 (8.0%)
   Dysplastic naevus                     n=1 (0.6%)             n=0
  Body site of lesion                                           
   Nose                                  n=108 (70.1%)          n=15 (60.0%)
   Ear                                   n=46 (29.9%)           n=10 (40.0%)
  Smoker                                 n=13 (8.4%)            n=1 (4.0%)
  Diabetes mellitus                      n=18 (11.6%)           n=2 (8.0%)
  User of anticoagulant medication       n=38 (24.7%)           n=7 (28.0%)
  User of immunosuppressive medication   n=2 (1.3%)             n=0

Four participants violated protocol because of the need for a wider excision (1) or the doctor or patient changing their mind about having flap or graft surgery after the antibiotic or placebo had been given (3). Due to death from unrelated causes during the postoperative study period (1) or failure to respond to repeated telephone follow-up (7) eight participants were lost to follow-up. These 12 participants who did not complete the study as intended ([table 2](#T2){ref-type="table"}) were more likely to be smokers (3) or study controls (8) than participants who did complete the study.

###### 

Comparison analyses of participants who completed the study to those who did not complete the study

  --------------------------------------------------------------------------------------------------------
  Characteristic                         Participants completing study (n=142)   Participants not\
                                                                                 completing study (n=12)
  -------------------------------------- --------------------------------------- -------------------------
  Control group                          n=69 (48.6%)                            n=8 (66.6%)

  Mean age (SD) (years)                  66.2 (11.1)                             67.5 (11.2)

  Male                                   n=77 (54.2%)                            n=6 (50.0%)

  Histology of lesion                                                            

   BCC                                   n=107 (75.4%)                           n=10 (83.3%)

   SCC                                   n=15 (10.6%)                            n=1 (8.3%)

   IEC                                   n=19 (13.4%)                            n=1 (8.3%)

   Dysplastic naevus                     n=1 (0.7%)                              n=0

  Body site of lesion                                                            

   Nose                                  n=100 (70.4%)                           n=8 (66.7%)

   Ear                                   n=42 (29.6%)                            n=4 (33.3%)

  Smoker                                 n=10 (7.0%)                             n=3 (25.0%)

  Diabetes mellitus                      n=16 (11.3%)                            n=2 (16.7%)

  User of anticoagulant medication       n=36 (25.4%)                            n=2 (16.7%)

  User of immunosuppressive medication   n=2 (1.4%)                              n=0

  Median time to surgery (IQR) (min)     50 (45--55)                             45 (36.25--50)
  --------------------------------------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows that the randomisation was mostly successful creating comparable groups at baseline. However, there were more male patients in the control group (63.8% vs 45.2%).

###### 

Baseline comparison of intervention group (n=73) with control group (n=69)

  Characteristic                         Intervention group (n=73)   Control group (n=69)
  -------------------------------------- --------------------------- ----------------------
  Mean age (SD) (years)                  66.6 (11.5)                 65.9 (10.8)
  Male                                   n=33 (45.2%)                n=44 (63.8%)
  Histology of lesion                                                
   BCC                                   n=55 (75.3%)                n=52 (75.4%)
   SCC                                   n=7 (9.6%)                  n=8 (11.6%)
   IEC                                   n=10 (13.7%)                n=9 (13.0%)
   Dysplastic naevus                     n=1 (1.4%)                  n=0
  Body site of lesion                                                
   Nose                                  n=55 (75.3%)                n=45 (65.2%)
   Ear                                   n=18 (24.7%)                n=24 (34.8%)
  Smoker                                 n=4 (5.5%)                  n=6 (8.7%)
  Diabetes mellitus                      n=8 (11.0%)                 n=8 (11.6%)
  Anticoagulant medication               n=19 (26.0%)                n=17 (24.6%)
  Immunosuppressive medication           n=1 (1.4%)                  n=1 (1.4%)
  Median time to surgery (IQR) (min)     50 (45--55)                 50 (45--55)
  Modified MMS\*                         n=10 (13.7%)                n=12 (17.4%)
  Surgical repair technique                                          
   Flap repair                           n=68 (94.5%)                n=58 (88.4%)
   Skin graft                            n=3 (4.1%)                  n=6 (8.7%)
   Wedge excision                        n=1 (1.4%)                  n = 2 (2.9%)
  Median defect size (IQR); range (mm)   13 (11.5--16); 9--25        14 (12--16.5); 9--30

\*Delayed surgical closure awaiting complete histological margin analysis.

MMS, Mohs micrographic surgery.

Surgical site infection {#s3a}
-----------------------

The main analysis based on available cases at follow-up ([table 4](#T4){ref-type="table"}) showed that one (1.4%; n=73) SSI occurred in the intervention group compared with eight (11.6%; n=69) in the control group (p=0.015).

###### 

SSI analysis of available cases, stratified by sex

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                  Antibiotic Prophylaxis   Control group   P values    Absolute risk reduction   95% CI         Relative risk reduction (%)   NNTB (95% CI)
  ----------------------------------------------- ------------------------ --------------- ----------- ------------------------- -------------- ----------------------------- ------------------------------------------
  Analysis of available cases                                                                                                                                                 

                                                  n=73                     n=69                                                                                               

   No of SSI                                      n=1                      n=8                                                                                                

   Incidence rate of SSI                          1.4%                     11.6%           P=0.015\*   10.2%                     2.2 to 18.2    87.9                          9.8 (5.5 to 45.5)

  Analysis of available cases stratified by sex                                                                                                                               

  Male                                            n=33                     n=44                                                                                               

   Incidence rate of SSI                          0%\                      15.9% (n=7)     P=0.018\*   15.9%                     5.2 to 26.6    100                           6.3 (3.8 to 19.2)
                                                  (n=0)                                                                                                                       

  Female                                          n=40                     n=25                                                                                               

   Incidence rate of SSI                          2.5%\                    4.0%\           P=1.0\*     1.5%                      −7.6 to 10.6   37.5                          66.7 (NNTH 13.2 to infinity to NNTB 9.4)
                                                  (n=1)                    (n=1)                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P values are results of Fisher's exact test.

NNTB, number needed to treat for benefit; NNTH, number needed to treat for harm; SSI, surgical site infection.

The difference in incidence of infection was 10.2% (95% CI 2.2% to 18.2%). The NNTB was 9.8 (95% CI 5.5 to 45.5). These results were confirmed by the ITT analyses ([table 5](#T5){ref-type="table"}) assuming both that (1) none of the 12 cases lost to follow-up had developed SSI (p=0.034) and (2) all 12 cases had developed SSI (p=0.017).

###### 

SSI analysis by 'ITT' assuming (1) all and (2) none of the participants violating protocol or lost to follow-up would have developed SSI

                                                                                                                        Antibiotic Prophylaxis   Control group   P values    Absolute risk reduction   95% CI        Relative risk reduction (%)   NNTB (95% CI)
  --------------------------------------------------------------------------------------------------------------------- ------------------------ --------------- ----------- ------------------------- ------------- ----------------------------- --------------------
  Analysis by ITT: assuming all the participants violating protocol or lost to follow-up would have developed SSI                                                                                                                                  
                                                                                                                        n=77                     n=77                                                                                              
  No of SSI                                                                                                             n=1                      n=8                                                                                               
  Incidence rate of SSI                                                                                                 1.3%                     10.4%           P=0.034\*   9.1%                      1.8 to 16.4   87.5                          11.0 (6.1 to 55.6)
  Analysis by ITT: assuming none of the participants violating protocol or lost to follow-up would have developed SSI                                                                                                                              
                                                                                                                        n=77                     n=77                                                                                              
  No of SSI                                                                                                             n=5                      n=16                                                                                              
  Incidence rate of SSI                                                                                                 6.5%                     20.8%           P=0.017\*   14.3%                     3.7 to 24.9   68.8                          7.0 (4.0 to 27.0)

\*P values are results of Fisher's exact test.

ITT, intention-to-treat; NNTB, number needed to treat for benefit; NNTH, number needed to treat for harm; SSI, surgical site infection.

SSI-stratified analysis by sex {#s3b}
------------------------------

Giving cephalexin prior to surgery significantly reduced SSI in men ([table 4](#T4){ref-type="table"}) with 7 of the 44 controls and none of the 33 intervention participants developing infection (p=0.018). Antibiotic prophylaxis resulted in an absolute SSI reduction of 15.9% (95% CI 5.2% to 26.6%) and a relative SSI reduction of 100% in men. In order to prevent one infection in male participants, 6.3 men need to be treated (95% CI 3.8 to 19.2).

Antibiotic prophylaxis made no difference to the low rate of SSI in women with one control (n=25) and one intervention participant (n=40) developing infection (p=1.0).

Regardless of group allocation, none of the participants who had modified MMS (delayed closure following complete histological margin analysis) developed SSI.

Swab results for SSI cases {#s3c}
--------------------------

For the nine participants who developed SSI ([table 6](#T6){ref-type="table"}), eight had swabs taken for microscopy, culture and sensitivity.

###### 

Details of participants that developed SSI

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Gender   Study group    Body site   Modified\   Surgical repair   Other complications   Organism isolated on swab MC&S   Sensitivity to cephalexin
                                      MMS\*                                                                                
  -------- -------------- ----------- ----------- ----------------- --------------------- -------------------------------- ---------------------------
  Male     Control        Ear         No          Graft             Nil                   *Staphylococcus aureus*          Yes

  Male     Control        Ear         No          Graft             Nil                   *S. aureus*                      Yes

  Male     Control        Nose        No          Flap              Nil                   *Hafnia alvei*                   No

  Male     Control        Ear         No          Flap              Nil                   *S. aureus*                      Yes

  Male     Control        Ear         No          Flap              Nil                   *S. aureus*                      Yes

  Male     Control        Nose        No          Flap              Nil                   *S. aureus*                      Yes

  Male     Control        Nose        No          Flap              Nil                   GP without swab                  Unknown

  Female   Control        Nose        No          Flap              Nil                   *S. aureus*                      Yes

  Female   Intervention   Ear         No          Flap              Nil                   *Pseudomonas aeruginosa*         No
  ----------------------------------------------------------------------------------------------------------------------------------------------------

\*Delayed surgical closure awaiting complete histological margin analysis.

GP, general practitioner; MC&S, Microscopy, Culture and Sensitivity; MMS, Mohs micrographic surgery; SSI, surgical site infection.

Cephalexin-sensitive *S. aureus* was confirmed in six participants. In one participant cephalexin-resistant *Hafnia alvei* infection was confirmed; the infection had already responded clinically to prescribed cephalexin by the time the microbiology report was available. *Pseudomonas aeruginosa* was confirmed in a control participant following an ear wound repair; this settled quickly once antibiotics were changed to the quinolone ciprofloxacin in accordance with culture sensitivity. The final participant with SSI inadvertently attended his general practitioner who prescribed flucloxacillin without taking a swab for culture and sensitivity. At the time of suture removal at the study practice, review of a photograph taken by the participant before antibiotics had been prescribed confirmed SSI clinically.

Secondary outcome measures {#s3d}
--------------------------

With respect to postoperative complications other than infection ([table 7](#T7){ref-type="table"}), there was no difference between the study groups (p=0.364) with two postoperative haemorrhages (both intervention), one flap necrosis (control) and one wound dehiscence (intervention).

###### 

Comparison of study groups with respect to postoperative complications and adverse events

  -----------------------------------------------------------------------------------
  Outcome characteristic      Antibiotic\          Control group (n=69)   P values
                              prophylaxis (n=73)                          
  --------------------------- -------------------- ---------------------- -----------
  Complications                                                           P=0.364\*

   None                       n=70 (95.9%)         n=68 (98.6%)           

   Bleeding postoperatively   n=2 (2.7%)           n=0                    

   Flap necrosis              n=0                  n=1 (1.4%)             

   Wound dehiscence           n=1 (1.4%)           n=0                    

  Adverse events                                                          P=0.871\*

   None                       n=71 (97.3%)         n=68 (98.6%)           

   Nausea                     n=1 (1.4%)           n=1 (1.4%)             

   Diarrhoea                  n=1 (1.4%)           n=0                    
  -----------------------------------------------------------------------------------

\*P values are results of Fisher's exact test.

Furthermore, there was no significant difference between the study groups in adverse symptoms ([table 7](#T7){ref-type="table"}) that might have been attributable to high-dose antibiotic administration (p=0.871) with one participant from each study group suffering some nausea and mild diarrhoea being reported in one intervention participant.

Discussion {#s4}
==========

Though infection rates are generally very low for clean dermatological surgery,[@R1] a significant increase in SSI is observed for surgery on the ear and nose compared with other body sites.[@R14] Of all body sites the nose and ear have the greatest concentration of sebaceous glands. With the latter being heavily colonised by bacteria, the increased risk of SSI on the nose and ear may be explained. Furthermore, with the nares being a principal source of *S. aureus*, it is postulated that its proximity puts nasal skin incisions at higher risk of infection still.

Complex wound closures have consistently been linked with greater risk of SSI than simple closures.[@R14] In a large prospective study involving 3491 surgical dermatological procedures, Rogues *et al* observed that the difference in infection rates following flap and graft closure (14.7%) rather than simple closure (1.7%) was even more marked when clean rather than sterile gloves were worn.[@R19] For complex dermatological closures also involving the nose and ear, Sylaidis *et al* found a much higher infection rate (6 of 27) than they did for complex skin closures elsewhere on the face (3 of 43).[@R14]

The evidence to support or refute the use of oral antibiotic prophylaxis for dermatological surgery at higher risk of SSI is scant.[@R3] Though overt infection was seen in none of 30 randomised controlled trial (RCT) patients undergoing full thickness graft reconstruction surgery on the nose, Kuijpers *et al* found the graft survival was better for those randomised to antibiotic prophylaxis (azithromycin for 3 days).[@R22] Subanalysis of 60 reconstructive dermatological flap procedures in an RCT confirmed that antibiotic prophylaxis resulted in significantly fewer SSIs.[@R23] In a small non-randomised observational study involving 18 patients having facial graft surgery for Non Melanotic Skin Cancer (NMSC), Saleh *et al* observed that antibiotic prophylaxis resulted in significantly less infection, graft loss and graft necrosis.[@R24] Conversely, in an RCT involving 82 patients undergoing secondary intention healing following auricular Mohs surgery, Mailler-Savage *et al* found no difference in wound healing or SSI with antibiotic prophylaxis (levofloxacin).[@R25]

In our RCT for patients having complex cutaneous repair on the nose and ear, a significant reduction in SSI was found following antibiotic prophylaxis. Although our baseline infection rate was lower than anticipated (11.6% rather than 20%), the study was still adequately powered to assess the effect of antibiotic prophylaxis as the intervention group had more than the fivefold reduction in infection rate (to 1.4%) that had been anticipated for the purpose of sample size calculation.

Our main analysis is presented as an available case analysis. The Cochrane definition of ITT is the analysis of all randomised participants even if they have violated the protocol or been lost to follow-up. We, therefore, imputed data for the 12 participants for whom we had been unable to collect outcome data ([table 5](#T5){ref-type="table"}). Our results remained significant regardless of whether those violating protocol and lost to follow-up had all developed SSI or all remained free of infection.

As sex was identified as a confounder, the analysis was stratified by sex. The benefit of antibiotic prophylaxis was clear in men. Just one of the 25 female controls developed SSI. The authors consider this too low an infection risk to justify routine antibiotic prophylaxis. Furthermore, no reduction in SSI was observed in the 40 women given antibiotic prophylaxis. It needs to be acknowledged, however, that due to the low baseline infection rate in women, the study was underpowered to draw conclusions regarding the effect of antibiotic prophylaxis in this subgroup.

Rogues *et al* also found that gender was an independent risk factor for SSI following complex reconstructive skin surgery with 6.3% of men and 1.1% of women developing infection.[@R19] Men are known to have higher sebum production and thicker skin than women particularly following menopause.[@R26] The higher concentration of pilosebaceous units on the thicker glabrous skin of the ear and nose in men may mean an increased bacterial skin commensal load at these sites explaining the marked gender difference in SSI found in our study.

With no difference between the study groups in adverse symptoms that might have been attributable to the administration of a single high-antibiotic dose, our study confirms that 2 g oral cephalexin is well tolerated. Other studies have confirmed that higher-dose short-term antibiotics have no increased side effects compared with lower dose longer-term antibiotic courses.[@R27]

Though higher infection rates have been observed following MMS on the nose than other body sites,[@R16] studies confirm that SSI is generally low following MMS.[@R2] The modified MMS we used, leaving wounds open under a dressing for up to 48-hour awaiting histology, was not associated with any increase in SSI compared with wounds closed immediately following excision.

Conclusion {#s5}
==========

With indiscriminate use of antibiotics causing the emergence of ever more antibiotic-resistant pathogens, antibiotics should always be prescribed with caution. Where antibiotic prophylaxis has been shown to be both warranted and effective its use preoperatively may be justified. Furthermore, antibiotic resistance may be less likely following a single high-antibiotic prophylactic dose than following prolonged antibiotic treatment of an established infection.

In our study, an unacceptably high rate of SSI was observed following complex auricular and nasal dermatological repair. A single high-dose preoperative oral antibiotic significantly reduced SSI. The effect was significant in men but not women. Additionally, a bolus oral dose of 2 g cephalexin dose was well tolerated with no measurable increase in adverse effects compared with placebo.
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